Spero Therapeutics, Inc. (SPRO) — Analyst outlook / Analyst consensus target is. Based on 13 analyst ratings, the consensus is bullish — 6 Buy, 5 Hold, 2 Sell.
Analysts estimate Earnings Per Share (EPS) of $-0.92 and revenue of $0.04B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.27 vs est $-0.92 (missed -38%). 2025: actual $0.15 vs est $-0.10 (beat +250%). Analyst accuracy: 3%.
SPRO Analyst Ratings
Buy
Based on 13 analysts giving stock ratings to Spero Therapeutics, Inc. in the past 3 months
EPS Estimates — SPRO
3%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.27
vs Est –$0.92
▼ 27.6% off
2025
Actual $0.15
vs Est –$0.10
▲ 166.7% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — SPRO
50%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.027B
vs Est $0.039B
▼ 42.2% off
2025
Actual $0.060B
vs Est $0.026B
▲ 57.2% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
